SDL PLC Launch of SDL Multilingual Submission Management
October 24 2017 - 8:00AM
RNS Non-Regulatory
TIDMSDL
SDL PLC
24 October 2017
RNS Reach
SDL Announces General Availability of SDL Multilingual
Submission Management
Solution Developed Specifically for Global Multilingual
Regulatory Submissions
MAIDENHEAD, UK - October 24, 2017 - SDL (LSE: SDL) has announced
the availability of SDL Multilingual Submission Management (MSM), a
web-based platform that enables biopharmaceutical firms to globally
automate the submission of multilingual marketing authorization
applications to regulatory authorities across 100+ languages and
markets.
Operating in one of the most demanding and highly regulated
environments, pharmaceutical organizations face the constant
challenge of filing, updating and maintaining medicinal product
information globally. High standards demanded by local regulatory
agencies during the submissions process - which varies by country -
puts enormous pressure on firms to ensure every element of their
application is flawless. Formatting and translation errors can
delay timelines by weeks or even months.
SDL MSM enables these organizations to overcome all the
multilingual challenges associated with regulatory labelling and
submission, providing the industry's first dedicated platform for
centrally managing this process globally. Based on market validated
technologies that have helped many pharmaceutical organizations
manage their global regulatory labelling submissions for the past
decade, SDL MSM also combines a rich set of features that make it
simple to manage the complete submission process from a single
dashboard.
"Submitting local language documents for regulatory approval
with one regulatory agency is difficult enough - let alone across
dozens of countries where documents need to be translated,
reformatted, and orchestrated in a timely fashion," said Kaarin
Gordon, SVP of global life sciences, SDL. "Our proven success in
this area for the past decade - combined with the exciting new
web-based features that SDL MSM offers - make it a powerful
platform to overcome one of the biggest burdens for international
regulatory affairs departments."
Announced at the Global Pharmaceutical Regulatory Affairs
Summit, Prague, SDL MSM offers easier, faster and lower cost
deployment - with greater availability of services.
About SDL
SDL (LSE:SDL) is the global innovator in language translation
technology, services and content management. Over the past 25 years
we've helped companies deliver transformative business results by
enabling powerful, nuanced digital experiences with customers
around the world. Are you in the know? Find out why 78 out of the
top 100 global brands work with us at SDL.com and follow us on
LinkedIn, Twitter and Facebook.
Contacts:
SDL
Denis Davies
Ddavies@sdl.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKZLBLDBFXFBB
(END) Dow Jones Newswires
October 24, 2017 08:00 ET (12:00 GMT)
Sdl (LSE:SDL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sdl (LSE:SDL)
Historical Stock Chart
From Jul 2023 to Jul 2024